Search Results

Prostate cancer is the most commonly diagnosed cancer in American men and the third leading cause of cancer-related deaths. However, the decision whether to pursue early detection of prostate cancer is complex; because not all men with prostate cancer will die of this disease, treatment is not necessary for some. These guidelines are intended to help men and clinicians choose a program for early detection of prostate cancer and make decisions about the need for prostate biopsy.

For the most recent version of the guidelines, please visit NCCN.org

To properly identify and treat patients with prostate cancer, physicians must have an in-depth understanding of the natural history and diagnostic, staging, and treatment options. Prostate cancer is a complex disease, with many controversial aspects of management and a dearth of sound data to support recommendations. Several variables must be considered in tailoring prostate cancer therapy to each individual patient. These guidelines provide a framework on which to base treatment decisions. Important changes to the guidelines since last publication include the introduction of Principles of Life Expectancy Estimation table and changes in recommendations for both hormone and chemotherapy.

For the most recent version of the guidelines, please visit NCCN.org